Pharmaceutical intermediates
Eltrombopag Olamine Intermediates
7 pharmaceutical intermediates for Eltrombopag Olamine. Indication: Aplastic Anemia; Thrombocytopenia; Idiopathic Thrombocytopenic Purpura (ITP); Chronic Hepatitis C.
About Eltrombopag Olamine
- Originator
- Glaxosmithkline (Gsk)
- Indication
- Aplastic Anemia; Thrombocytopenia; Idiopathic Thrombocytopenic Purpura (ITP); Chronic Hepatitis C
- Approved Date
- 09/08/2009
- DS/DP
- 07/13/2025
Available intermediates
7 intermediates currently listed for Eltrombopag Olamine. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3'-Amino-2'-Hydroxybiphenyl-3-Carboxylic Acid | 376592-93-7 | / | / |
| 2'-Hydroxy-3'-Nitro-Biphenyl-3-Carboxylic Acid | 376591-95-6 | / | / |
| 2'-Methoxy-3'-Nitro-Biphenyl-3-Carboxylic Acid | 376591-94-5 | / | / |
| 3-Methyl-1-(3,4-dimethylphenyl)-2-pyrazolin-5-one | 18048-64-1 | / | / |
| 2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one | 277299-70-4 | / | / |
| 1-Bromo-2-Methoxy-3-Nitrobenzene | 98775-19-0 | / | / |
| 2-(benzyloxy)-1-bromo-3-nitrobenzene | 688363-79-3 | / | / |
Building toward Eltrombopag Olamine?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →